TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC

Condition:   Hepatocellular Carcinoma Non-resectable Intervention:   Drug: TACE combined with sintilimab and bevacizumab Sponsor:   Second Affiliated Hospital of Guangzhou Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials